JP7231549B2 - 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 - Google Patents

抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 Download PDF

Info

Publication number
JP7231549B2
JP7231549B2 JP2019542388A JP2019542388A JP7231549B2 JP 7231549 B2 JP7231549 B2 JP 7231549B2 JP 2019542388 A JP2019542388 A JP 2019542388A JP 2019542388 A JP2019542388 A JP 2019542388A JP 7231549 B2 JP7231549 B2 JP 7231549B2
Authority
JP
Japan
Prior art keywords
amino acid
antibody
polypeptide
region
kabat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505054A5 (cg-RX-API-DMAC10.html
JP2020505054A (ja
Inventor
ウェイン エー． マラスコ
クアン カレン ジュー
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2020505054A publication Critical patent/JP2020505054A/ja
Publication of JP2020505054A5 publication Critical patent/JP2020505054A5/ja
Priority to JP2022211496A priority Critical patent/JP7606501B2/ja
Application granted granted Critical
Publication of JP7231549B2 publication Critical patent/JP7231549B2/ja
Priority to JP2024218361A priority patent/JP2025028191A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019542388A 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法 Active JP7231549B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022211496A JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2024218361A JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455245P 2017-02-06 2017-02-06
US62/455,245 2017-02-06
PCT/US2018/017027 WO2018145075A1 (en) 2017-02-06 2018-02-06 Compositions and methods for augmenting antibody mediated receptor signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022211496A Division JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020505054A JP2020505054A (ja) 2020-02-20
JP2020505054A5 JP2020505054A5 (cg-RX-API-DMAC10.html) 2021-03-18
JP7231549B2 true JP7231549B2 (ja) 2023-03-01

Family

ID=63040120

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019542388A Active JP7231549B2 (ja) 2017-02-06 2018-02-06 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2022211496A Active JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022211496A Active JP7606501B2 (ja) 2017-02-06 2022-12-28 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法
JP2024218361A Pending JP2025028191A (ja) 2017-02-06 2024-12-13 抗体媒介性受容体シグナル伝達を増強するための組成物及び方法

Country Status (7)

Country Link
US (2) US20220213206A1 (cg-RX-API-DMAC10.html)
EP (1) EP3576793A4 (cg-RX-API-DMAC10.html)
JP (3) JP7231549B2 (cg-RX-API-DMAC10.html)
CN (1) CN110520158A (cg-RX-API-DMAC10.html)
AU (2) AU2018215673B2 (cg-RX-API-DMAC10.html)
CA (1) CA3049689A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018145075A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031194A1 (en) * 2016-07-22 2018-01-25 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
RU2734432C1 (ru) * 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
WO2022241182A1 (en) * 2021-05-13 2022-11-17 Arizona Board Of Regents On Behalf Of Arizona State University A plant produced anti-egfr mabs with specific glycosylation to improve the efficacy against cancer
CN115873126A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 人生长激素融合蛋白及其制备和用途
CA3263665A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anti-CLDN4 antibodies and their methods of use
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139365A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2015200990B2 (en) * 2009-03-20 2016-07-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Optimized Fc variants
WO2014006217A1 (en) * 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
MX387324B (es) * 2013-01-10 2025-03-18 Genmab Bv Variantes de regiones fc de igg1 de humano y usos de las mismas.
JP6636803B2 (ja) * 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
DK3189081T3 (da) * 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
EP3526257A2 (en) * 2016-10-14 2019-08-21 Dana-Farber Cancer Institute, Inc. Modular tetravalent bispecific antibody platform
EP3535291A1 (en) * 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139365A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use

Also Published As

Publication number Publication date
JP2023036899A (ja) 2023-03-14
AU2018215673A1 (en) 2019-07-25
US20240336694A1 (en) 2024-10-10
AU2025202811A1 (en) 2025-05-08
CN110520158A (zh) 2019-11-29
JP7606501B2 (ja) 2024-12-25
EP3576793A4 (en) 2021-03-31
WO2018145075A1 (en) 2018-08-09
JP2025028191A (ja) 2025-02-28
AU2025202811A9 (en) 2026-03-05
CA3049689A1 (en) 2018-08-09
US20220213206A1 (en) 2022-07-07
AU2018215673B2 (en) 2025-01-23
EP3576793A1 (en) 2019-12-11
JP2020505054A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
US20240336694A1 (en) Compositions and methods for augmenting antibody mediated receptor signaling
US20250066481A1 (en) Fc variant compositions and methods of use thereof
US8952134B2 (en) Hybrid constant regions
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
JP7294758B2 (ja) 抗ｃｄ２４組成物及びその使用
JP2022513432A (ja) 免疫細胞活性化のための二重特異性抗体
WO2020244526A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
JP2020511997A (ja) 腫瘍抗原提示誘導物質構築物及びその使用
JP2025540657A (ja) 抗ｃｄ３抗体
KR20250129817A (ko) D-도메인 함유 폴리펩티드 및 그의 용도
JP7715722B2 (ja) 抗ｃｄ１３７コンストラクト及びその使用
WO2022116079A1 (zh) 一种抗ceacam5的人源化抗体及其制备方法和用途
WO2025049915A1 (en) Ilt2 binding agents and uses thereof
WO2024233955A1 (en) Agents that bind to cd16a and uses thereof
CN117715934A (zh) 抗cd3构建体及其用途
WO2022098910A1 (en) Icos antibodies for treatment of lymphomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190911

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230110

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230216

R150 Certificate of patent or registration of utility model

Ref document number: 7231549

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250